GBC Blog
Help Protect the Breakthroughs of Tomorrow (www.innovation.com)
In recent years, rapid advances in scientific discovery have ushered in a new era of medicine. But despite progress, Washington is considering policies that threaten the ability of America’s biopharmaceutical researchers to continue researching and developing new treatments and cures. We’re advocating for the latest innovations so we can continue to go boldly, together. www.innovation.org http://innovation.org/about-us/campaigns/breakthrough
Read MoreGeisinger to Offer DNA Sequencing to All Its Patients
Philadelphia Business Journal, May 7, 2018, 11:34am EDTPennsylvania-based Geisinger Health System is taking routine health screenings for patients beyond the typical mammograms, colonoscopies and cholesterol tests. It will soon be adding DNA sequencing to its list of recommended preventative care measures for patients. “Understanding the genome warning signals of every patient will be an essential…
Read MoreDiscovery Life Sciences Launches Major European Expansion
HUNTSVILLE, Ala., Feb. 13, 2019 /PRNewswire/ — Discovery Life Sciences™ (Discovery) announced a major expansion into Europe today, acquiring Sofia Bio and its extensive network of human biospecimen collection sites in Bulgaria, Romania, Poland, and the Czech Republic. Discovery also has entered into an agreement to become the exclusive industry distributor of East West Biopharma, which maintains the largest biocollection network in Ukraine. These initiatives cement…
Read MoreFour Life Science Companies Merge into Discovery Life Sciences
Published: Oct 16, 2018 By Mark Terry Discovery Life Sciences, a leading research biobank located in Los Osos, California, recently got much, much bigger via a four-company merger. Ann Dover, Discovery’s founder, president and chief executive officer, took time to speak with BioSpace about the merger and the new identity of the company. The four companies involved in the…
Read MoreOnly a Tenth of the Human Genome is Studied
The Economist / Science and Technology, Sep 20th 2018 ONE tale of Nasreddin, a self-satirising 13th-century philosopher, tells of the time he lost a precious ring. When his wife asks why he is searching in the yard rather than inside, where the ring was lost, Nasreddin explains that the light is better outside. Looking for…
Read MoreDiscovering the Ancient Origin of Cystic Fibrosis, The Most Common Genetic Disease in Caucasians
https://theconversation.com/discovering-the-ancient-origin-of-cystic-fibrosis-the-most-common-genetic-disease-in-caucasians-100499 Imagine the thrill of discovery when more than 10 years of research on the origin of a common genetic disease, cystic fibrosis (CF), results in tracing it to a group of distinct but mysterious Europeans who lived about 5,000 years ago. CF is the most common, potentially lethal, inherited disease among Caucasians – about…
Read MoreThe New Era of Medicine (www.innovation.org)
WELCOME TO THE NEW ERA OF MEDICINE Finding lifesaving treatments is our life’s work—the work of the 140,000 biopharmaceutical researchers who boldly leap into the unknown to pioneer tomorrow’s breakthrough cures. It’s also the work of millions of patients who fight against whatever obstacles they face. http://innovation.org/ http://innovation.org/latest-articles
Read MoreSeattle’s INDI Acquired by Lung Cancer Tech Company Biodesix
Seattle’s Integrated Diagnostics Acquired by Lung Cancer Technology Company Biodesix Colorado-based Biodesix, a company that creates technology around lung cancer, announced that it has acquired Seattle’s Integrated Diagnostics for an undisclosed sum. Integrated Diagnostics, also known as Indi, develops a test that can rule out patients who do not have lung cancer using a simple…
Read MoreFighting Antimicrobial Resistance with Fast Molecular Diagnostics
Clara Rodríguez Fernández on 3-July-2018 Antimicrobial resistance is predicted to kill more people than cancer by 2050. Is it possible to prevent it? At our Refresh Meetup in Berlin, I talked with Achim Plum, CBO of the diagnostics company Curetis, about what are our best bets to turn the tables in the fight against the threat…
Read MoreHHS Delays Common Rule for Another Six Months
HHS Delays Common Rule for Another Six Months June 19, 2018 Delays are becoming commonplace when it comes to the Common Rule. The U.S. Department of Health and Human Services (HHS) just announced it is delaying, again, rollout of the revised Common Rule on the protection of human subjects in clinical trials for six months—until…
Read More